---
schema_version: "secwatch.filing_event.v1"
accession: "0001447362-24-000121"
form_type: "8-K"
ticker: "CSTL"
cik: "0001447362"
company_name: "CASTLE BIOSCIENCES INC"
filed_at: "2024-08-05T23:59:59+00:00"
generated_at: "2026-05-31T13:03:42.682634+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Castle Biosciences Q2 revenue jumps 74% to $87M; raises FY2024 guidance to $275-300M

## Summary
- Revenue $87.0M (+74% YoY); net income $8.9M vs loss of $18.8M in Q2 2023.
- Total test reports 25,102 (+49% YoY); TissueCypher +230%, DecisionDx-SCC +60%.
- Raises FY2024 revenue guidance to $275-300M from prior $255-265M.
- Adjusted EBITDA $21.5M vs ($5.3M) in Q2 2023; gross margin 81%.
- Cash and investments $259.7M; net cash from operations $24.0M.

## SEC filing metadata
- accession: 0001447362-24-000121
- form_type: 8-K
- ticker: CSTL
- cik: 0001447362
- company_name: CASTLE BIOSCIENCES INC
- filed_at: 2024-08-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1447362/000144736224000121/0001447362-24-000121-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1447362/000144736224000121/cstl-20240805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001447362-24-000121
- JSON: https://secwatch.observer/filing/0001447362-24-000121.json
- Plain text: https://secwatch.observer/filing/0001447362-24-000121.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.